NUS Scientists Innovate Breast Cancer Therapy Using Electromagnetic Pulses

Innovative Approach to Breast Cancer Treatment

Researchers from the National University of Singapore (NUS) have recently unveiled an innovative strategy for treating breast cancer, utilizing pulsed electromagnetic fields (PEMFs). This groundbreaking technique focuses on reprogramming tumor-associated macrophages (TAMs), which are a type of immune cell that often aids in cancer growth, turning them into active agents against cancer cells.

Led by Associate Professor Alfredo Franco-Obregón from the NUS Yong Loo Lin School of Medicine and the NUS Institute for Health Innovation Technology, this study was published in the journal Smart Medicine on June 4, 2026. This latest research builds on prior findings indicating that brief exposure to PEMFs enhances the uptake of doxorubicin, a commonly used chemotherapy drug, by breast cancer cells.

How PEMF Therapy Works

The approach involves applying low-intensity magnetic pulses to targeted areas in the body over short time intervals. Franco-Obregón has previously investigated the influence of PEMFs on muscle growth and oncology. Notably, the NUS team found that in the absence of chemotherapy, the PEMF treatment successfully eradicated tumors in 75% of the preclinical models tested after just four sessions of 30 minutes each.

"Our study marks a significant step forward in breast cancer therapy, showcasing the potential of PEMFs as a standalone treatment that could spare patients from the side effects associated with chemotherapy," stated Assoc Prof Franco-Obregón.

The Growing Challenge of Breast Cancer

With incidents of breast cancer expected to increase by 33% from 2.3 million in 2023 to over 3.5 million by 2050, the urgency for innovative treatment options is paramount. The annual mortality rate may nearly double, highlighting the pressing need to tackle challenges like tumor heterogeneity, drug resistance, and the debilitating effects linked to conventional therapies. Previous strategies aimed at targeting TAMs have encountered issues related to off-target effects, making effective treatments more complex.

Understanding Tumor-Associated Macrophages (TAMs)

Breast cancer originates when cells within the breast begin to multiply uncontrollably, forming a lump. These malignant cells adeptly recruit nearby immune cells, corrupting them to support their survival and propagation. Among these, TAMs are frequently abundant in solid tumors. There are two main categories of macrophages: M1 and M2. M1 macrophages are known for their role in fighting off infections, while M2 macrophages assist in healing and can inadvertently promote cancer growth when hijacked by tumors.

The research emphasizes a crucial protein named TRPC1, which plays a key role in macrophage activation. According to the study, brief exposure to PEMFs activates TRPC1 channels on the M2-like TAMs, inducing a sequence of signals that convert them into the M1 state – effectively transforming these immune cells from passive protectors of the tumor into aggressive fighters that target cancerous cells.

Clinical Trials and Future Directions

Franco-Obregón noted that the PEMF device utilized in this research has successfully completed Phase 1 clinical trials, affirming its safety for human subjects. The team is actively seeking collaborators to initiate Phase 2 trials aimed at assessing the efficacy of PEMF therapy in patients and advancing towards clinical implementation.

"Given that we've previously shown PEMFs can enhance drug delivery of doxorubicin in breast cancer cells, we're keen to explore whether our PEMF therapy can work synergistically with conventional chemotherapy for improved outcomes," he added. "Since these reprogrammed immune cells are prevalent in various solid tumors, there is a hopeful perspective that PEMF therapy might extend its benefits to other cancer types beyond breast cancer."

In summary, this innovative study by NUS scientists opens up new avenues for breast cancer treatment, with the promise of a non-invasive method that could importantly reduce the dependency on traditional chemotherapy while improving patient outcomes.